Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

BACKGROUND: Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation. METHODS: A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17. RESULTS: KIT...

Descripción completa

Detalles Bibliográficos
Autores principales: Handolias, D, Hamilton, A L, Salemi, R, Tan, A, Moodie, K, Kerr, L, Dobrovic, A, McArthur, G A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856012/
https://www.ncbi.nlm.nih.gov/pubmed/20372153
http://dx.doi.org/10.1038/sj.bjc.6605635
_version_ 1782180226053177344
author Handolias, D
Hamilton, A L
Salemi, R
Tan, A
Moodie, K
Kerr, L
Dobrovic, A
McArthur, G A
author_facet Handolias, D
Hamilton, A L
Salemi, R
Tan, A
Moodie, K
Kerr, L
Dobrovic, A
McArthur, G A
author_sort Handolias, D
collection PubMed
description BACKGROUND: Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation. METHODS: A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17. RESULTS: KIT mutations were found in 38% of mucosal and in 6% of acral melanomas. Three patients were treated with imatinib and one with sorafenib. All four patients responded to treatment, but three have since progressed within the brain. CONCLUSION: The observed clinical responses support further investigation of KIT inhibitors in metastatic melanoma, selected according to KIT mutation status.
format Text
id pubmed-2856012
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28560122011-04-13 Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT Handolias, D Hamilton, A L Salemi, R Tan, A Moodie, K Kerr, L Dobrovic, A McArthur, G A Br J Cancer Clinical Study BACKGROUND: Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation. METHODS: A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17. RESULTS: KIT mutations were found in 38% of mucosal and in 6% of acral melanomas. Three patients were treated with imatinib and one with sorafenib. All four patients responded to treatment, but three have since progressed within the brain. CONCLUSION: The observed clinical responses support further investigation of KIT inhibitors in metastatic melanoma, selected according to KIT mutation status. Nature Publishing Group 2010-04-13 2010-04-06 /pmc/articles/PMC2856012/ /pubmed/20372153 http://dx.doi.org/10.1038/sj.bjc.6605635 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Handolias, D
Hamilton, A L
Salemi, R
Tan, A
Moodie, K
Kerr, L
Dobrovic, A
McArthur, G A
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
title Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
title_full Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
title_fullStr Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
title_full_unstemmed Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
title_short Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
title_sort clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in kit
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856012/
https://www.ncbi.nlm.nih.gov/pubmed/20372153
http://dx.doi.org/10.1038/sj.bjc.6605635
work_keys_str_mv AT handoliasd clinicalresponsesobservedwithimatiniborsorafenibinmelanomapatientsexpressingmutationsinkit
AT hamiltonal clinicalresponsesobservedwithimatiniborsorafenibinmelanomapatientsexpressingmutationsinkit
AT salemir clinicalresponsesobservedwithimatiniborsorafenibinmelanomapatientsexpressingmutationsinkit
AT tana clinicalresponsesobservedwithimatiniborsorafenibinmelanomapatientsexpressingmutationsinkit
AT moodiek clinicalresponsesobservedwithimatiniborsorafenibinmelanomapatientsexpressingmutationsinkit
AT kerrl clinicalresponsesobservedwithimatiniborsorafenibinmelanomapatientsexpressingmutationsinkit
AT dobrovica clinicalresponsesobservedwithimatiniborsorafenibinmelanomapatientsexpressingmutationsinkit
AT mcarthurga clinicalresponsesobservedwithimatiniborsorafenibinmelanomapatientsexpressingmutationsinkit

Ejemplares similares